[Madrid, Spain = E-Daily Reporter Kim Jinsoo ] Eleva Therapeutics, a subsidiary of HLB INC.(028300), is expected to be notified shortly of the review category—Class 1 or Class 2—regarding the U.S. Food and Drug Administration (FDA) approval of the combination therapy of riboceranib and camrelizumab for the treatment of liver cancer.

In addition, Eleva plans to submit a marketing authorization application for the riboceranib and camrelizumab combination therapy to the European Medicines Agency (EMA) by the first half of next year. Given the delay in FDA approval, the company intends to pursue EMA approval simultaneously.

Kim Dong-geon, CEO of Elevate Therapeutics, met with PharmIDaily on the 26th at the European Society for Medical Oncology (ESMO) conference in Madrid, Spain, and stated, “We expect to be notified soon regarding whether the review category for U.S. approval will be Class 1 or Class 2. We are shifting our strategy to proceed with preparations for an application to the European Medicines Agency (EMA) even before Riboceranib and Camrelizumab receive FDA approval.”

He added, “We are considering submitting a marketing authorization application to the EMA roughly in the first half of next year. We plan to proceed after reviewing the EMA’s pre-submission procedures and filing schedule.”

Elevate Therapeutics is developing the combination therapy of riboceranib and camrelizumab as a first-line treatment for hepatocellular carcinoma (HCC). Elevate Therapeutics submitted a New Drug Application (NDA) for the riboceranib-camrelizumab combination to the U.S. FDA but received three Complete Response Letters (CRLs) and has recently embarked on a fourth attempt.

Initially, Eleva Therapeutics and Hengrui Pharmaceuticals planned to apply for approval in Europe following approval in the U.S. However, as delays in U.S. approval began to affect their European expansion, they shifted their strategy to pursue approval in both the U.S. and Europe simultaneously.

CEO Kim stated, “The EMA requires a separate pre-submission process, and applications must be submitted according to a set schedule,” adding, “The exact timing of the application may vary slightly depending on our preparation status and the regulatory agency’s schedule.”

Unlike in the U.S., where the company is pursuing in-house commercialization, Elevate Therapeutics plans to sell its products in Europe through a partner. To this end, Elevate Therapeutics has already been in contact with several local European companies.

CEO Kim explained, “There is no change to our existing plan to handle commercialization in the U.S. on our own. In other regions, such as Europe, we are pursuing sublicensing agreements. We contacted a significant number of companies before receiving our first CRL and even discussed specific contract terms with some of them. We plan to determine whether to resume negotiations with these parties.”

In particular, since the combination therapy of Riboceranib and Camrelizumab is already included in the European Society for Medical Oncology’s treatment guidelines, rapid commercialization is expected if approval is granted.

CEO Kim stated, “While inclusion in the treatment guidelines is one thing, actual sales are another; commercialization is not possible without approval. Ultimately, approval from regulatory authorities must come first.”

Outlook for U.S. Approval Before European Application

While

a

marketing

authorization application in Europe

is scheduled for the first half of next year,

a decision on approval by the U.S.

FDA is expected before then. Elevate Therapeutics resubmitted a New Drug Application (NDA) for Riboceranib in the U.S. on October 9.

CEO Kim said, “The CRL issued last July was due to deficiencies identified during a routine Current Good Manufacturing Practice (cGMP) inspection of the manufacturing facilities related to riboceranib; as the specific details constitute confidential information belonging to Hangzhou Pharmaceutical, it is difficult to disclose them. Following the CRL, we received confirmation from Hangzhou Pharmaceutical on multiple occasions that the necessary preparations had been completed prior to resubmitting the application, and we verified the required items.”

He continued, “While Eleva may verify the relevant matters multiple times and request corrections, if the FDA conducts another on-site inspection, Hangzhou Pharmaceutical is ultimately responsible for addressing the issues. Hangzhou Pharmaceutical has made active efforts to correct the identified issues. The recent inspection results for the manufacturing facilities related to Riboceranib were classified as a ‘Voluntary Action Recommendation (VAI),’ which means no administrative or regulatory actions are taken or recommended, as opposed to an ‘Official Action Indicated (OAI).’”

The future schedule will depend on the FDA’s re-review classification. If the resubmitted data constitutes a complete response to the CRL findings, the FDA typically determines the review type—such as Class 1 or Class 2—within 30 days of receipt and provides guidance on the target processing date. The review period is two months for Class 1 and six months for Class 2, starting from the date of receipt. If classified as Class 1, a decision on approval is expected as early as this year.

CEO Kim explained, “Since we submitted the application on October 9, the review category is expected to be determined in early November. We could receive the results regarding the review category at any time, and we plan to announce it as soon as we are notified.” He added, “If classified as Class 1, the expected review deadline is December 9; if classified as Class 2, it is April 9 of next year.”

In particular, since the FDA’s decision is expected to influence EMA approval as well, the FDA’s decision is likely to carry even greater weight.

He said, “The EMA will naturally maintain the position that it conducts its review independently, regardless of whether the FDA grants approval. However, there may be pressure to avoid reaching different conclusions when reviewing the same clinical data. Realistically, if the FDA grants full approval for a drug, it is expected to serve as a positive factor in the EMA’s authorization review as well.”

In addition, CEO Kim stated, “While we are considering the possibility of developing other indications for riboceranib monotherapy, our top priority at present is hepatocellular carcinoma. If problems continue to arise in the future, we may consider other directions, but for now, we have no plans to change our strategy and will focus on obtaining approval for hepatocellular carcinoma.”